$MDGL CEO on CNBC https://t.co/OiJWmO6JLq
$ARDX https://t.co/xqltwKjBLc
$MDGL BofA another biotech BofA been wrong to long -raising forecasts to $2.7B from $2.0 prior, remain meaningfully below. After also incorporating recent OpEx trends, our PO increases to $239/share from $154/share prior, supporting our U/P rating
Tarsus Pharmaceuticals reported a fourth-quarter GAAP EPS of $(0.60), surpassing analysts' expectations of $(0.75). The company's sales reached $66.41 million, exceeding the projected $58.33 million. Following the earnings announcement, Tarsus' stock experienced a pre-market increase of 7.6%. In a separate development, Madrigal Pharmaceuticals announced its fourth-quarter results, posting a net loss of $(59.42) million and revenue of $103.32 million, which was above the estimated $97.8 million. The company reported net sales of $103 million for the full year 2024 and highlighted that over 11,800 patients are currently on its product, Rezdiffra. Madrigal's strong performance led to an increase in stock price, with analysts at Bank of America raising their price target for the company to $239 per share from $154, reflecting a positive outlook amid a challenging biotech environment.
